Tamir Kadishi is Head of the Finance Division at the Weizmann Institute of Science. Mr. Kadishi is a senior financial executive with extensive experience in corporate finance, financial reporting and strategic oversight across large industrial and scientific institutions. Prior to joining the Weizmann Institute in 2020, he served for over a decade as Chief Financial Officer of Haifa Chemicals Ltd. and previously as Chief Financial Officer of Africa Israel Industries Ltd., holding responsibility for financial management, organizational budgeting and corporate accounting functions.
Mr. Kadishi earned his B.A. in Accounting from Ben-Gurion University of the Negev and is a licensed CPA.

Prof. Boris Rybtchinski was born in Kiev, Ukraine, in 1971, and earned his B.Sc. from Kiev State University in 1992 before immigrating to Israel. He began his graduate studies at the Weizmann Institute of Science in 1993, completing his M.Sc. and later his Ph.D. under Prof. David Milstein in 2002. Following postdoctoral research at the Northwestern University with Prof. Michael Wasielewski, he joined the Weizmann Institute as a principal investigator in 2005. He was promoted to Full Professor in 2020 and, since December 2024, has served as Head of the Department of Molecular Chemistry and Materials Science.

Prof. Rybtchinski’s research integrates molecular chemistry with materials and energy technologies, focusing on the development of recyclable and adaptive nanomaterials as well as self-assembled systems for energy applications such as organic solar cells and batteries. Sustainable plastics are also a major research focus of the Rybtchinski group. Advanced electron microscopy plays a central role in this work, providing insights into self-assembly and crystallization processes that guide rational materials design.

Prof. Rybtchinski is the recipient of the Israel Chemical Society Adama Prize (2025), the Gutwirth Prize (2020) and the Weizmann Institute Scientific Council Prize (2012), and held the Werdelmann-Stiftung Lectureship at the University of Essen in 2013.

Dr. Anat Cohen-Dayag is a senior biotechnology executive with nearly three decades of leadership experience spanning therapeutic discovery and development, strategic partnering, corporate financing, global operations, and R&D innovation.
Dr. Cohen-Dayag currently serves as Executive Chair of the Board of Directors at Compugen. Prior to her appointment as Executive Chair, Dr. Cohen-Dayag served for 15 years as President and Chief Executive Officer of Compugen, where she led the company’s transformation from a computational biology service provider to a clinical-stage drug discovery and development company in the field of cancer immunotherapy, forging strategic collaborations with leading global pharmaceutical companies including AstraZeneca, Bayer, Bristol Myers Squibb and Gilead. Previously, she held various executive R&D roles at Compugen, overseeing the discovery and development of programs for novel therapeutic and diagnostic applications. Before joining Compugen, Dr. Cohen-Dayag held several senior R&D positions across multiple companies in the Israeli biotech industry.
Dr. Cohen-Dayag has extensive board experience across public and private companies contributing to innovation throughout the biotech ecosystem,. In addition, she mentors emerging CEOs and actively supports the advancement of women executives into C-suite leadership positions within the life sciences sector.
Dr. Cohen-Dayag earned her B.Sc. in Biology from Ben-Gurion University, her M.Sc. in Chemical Immunology and her Ph.D. in Cellular Biology from the Weizmann Institute of Science.